‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks


The Federal Trade Commission and seven states say Shkreli should be held in contempt

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *